Swiss Business News and Press Releases

Part of the HELP.CH ® Network


Swiss News Now is a news platform with the latest news and information from Swiss companies and Swiss authorities. Latest news from Switzerland in English.


Mexico first to approve Restylane Shaype for chin and jawline indications

Zug, Switzerland – Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.

Teenager killed over £20 drug debt | BBC News

Joshua Ingram was killed by a drug dealer over a £20 cannabis debt in September 2025.

Richemont concludes its 7th consecutive year at CIIE

The ninth China International Import Expo (CIIE) has successfully drawn to a close, marking the resounding culmination of Richemont’s seventh consecutive participation in the event. The occasion held particular significance as the Group marked the twentieth anniversary of its presence in China. Under the theme “Crafting Bonds: The Art of Human Connection”, Richemont brought together five of its Maisons in a carefully curated presentation of time-honoured masterpieces and new creations, revealing the enduring craftsmanship and human stories behind each work.

Rothschild & Co appoints Geoffroy de Ridder as Group Chief Technology and Operations Officer

Rothschild & Co is pleased to announce that it has appointed Geoffroy de Ridder as Group Chief Technology and Operations Officer (CTOO) and CTOO for its Wealth and Asset Management business, effective December 2026.

LEM delivers strong growth in bookings, sales and profitability in the first half of 2026/27

Bookings rose by 34.4% to CHF 201.7 million (H1 2025/26: CHF 150.1 million), driven primarily by Automation, Renewable Energy and Energy Distribution & High Precision. The book-to-bill ratio reached 1.16, pointing to a gradual recovery in demand.

Avaloq enters U.S. wealth market with launch of Avaloq Mosaic

Composable platform enables wealth managers to connect fragmented investment data, scale personalized portfolio management and add capabilities without replacing their existing technology stack.

Georg Wunderlin to succeed Boudewijn Beerkens as CEO of COFRA Holding AG

Zug, Switzerland – The Board of COFRA Holding AG (“COFRA”) announces the appointment of Georg Wunderlin as Chief Executive Officer (CEO) and a member of the COFRA Board of Directors, effective in April 2027.

Swiss Re delivers 3% increase in net income to USD 4.2 billion for the first nine months of 2026

Swiss Re reported a net income of USD 1.3 billion for the third quarter of 2026, resulting in a net income of USD 4.2 billion and a return on equity (ROE) of 22.5% for the first nine months of the year. The Group's financial performance benefited from strong contributions from all Business Units, supported by lower-than-expected natural catastrophe losses and a solid investment result. The Group and all Business Units are well on track towards their 2026 financial targets.

Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data supporting an attractive therapeutic window for MP0632, a logic-gated Switch-DARPin T cell engager (TCE) with integrated CD2 co-stimulation, at the Society for Immunotherapy of Cancer (SITC) 2026 conference.

Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder

Allschwil, Switzerland – Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in patients 10 to <18 years of age.

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

SAN CARLOS, Calif.-- BeOne Medicines Ltd. a global oncology company, today announced financial results and corporate updates from the third quarter of 2026.




HELP.CH

A Service by HELP.CH ®

HELP.CH® Logo

SwissNewsNow.com is a news platform focused on current developments from Switzerland and part of the HELP.CH ® network.

The platform provides readers with a compact overview of Swiss news, business developments, company information, innovation, technology and society. Selected content is sourced from the HELP.CH news network and related media platforms.

SwissNewsNow.com helps make important Swiss news accessible through structured publication, search engine visibility and distribution across digital channels.

More about the network:
help.swiss/en

The network includes news platforms such as Aktuellenews.ch, HELP.CH News, Swiss-Press.com, Tagesthemen.ch, Aktuellenews.de and Aktuellenews.at. Together they provide coverage of Swiss business, technology, innovation, society and economic developments.

SwissNewsNow.com brings together selected news and information from across the network, providing readers with a convenient gateway to relevant Swiss topics and current developments.